Sort   by:  
 Page size 
UnknownMolecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.
Not available
S-EPMC6369924 | biostudies-literature
UnknownClinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
Not available
S-EPMC9293196 | biostudies-literature
GenomicsHomo sapiens
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
PRJNA175066 | ENA
UnknownOrdered water molecules as key allosteric mediators in a cooperative dimeric hemoglobin.
Not available
S-EPMC26166 | biostudies-literature
UnknownDefinition and management of ruxolitinib treatment failure in myelofibrosis.
Not available
S-EPMC4315890 | biostudies-literature
UnknownMomelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.
Not available
S-EPMC10948874 | biostudies-literature
UnknownMPL-mutated essential thrombocythemia: a morphologic reappraisal.
Not available
S-EPMC6246562 | biostudies-literature
Unknown1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events.
Not available
S-EPMC9278284 | biostudies-literature
TranscriptomicsSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
17 patients with myelofibrosis contributed paired research samples; the time points were pre-study and 12 weeks after commencing study treatment with CYT387.Gene expression analysis was investigated to study the effects of drug treatment. Additional analysis invesitigated differences in expression p...
ORGANISM(S): Homo sapiens 
2013-01-14 | E-GEOD-40841 | biostudies-arrayexpress
UnknownSafety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Not available
S-EPMC4979099 | biostudies-literature
Sort   by:  
 Page size